Global health and vaccination: TB & beyond. Dr Mary Moran Executive Director

Transcription

1 Global health and vaccination: TB & beyond Dr Mary Moran Executive Director

2 Outline About Policy Cures 3 reasons to focus on vaccine innovation Where are we today? The pipeline Where are we today? The funding Australia and global health vaccine R&D

3 Innovative ideas and accurate analysis to accelerate development and uptake of new drugs, vaccines, diagnostics and other products for neglected diseases of the developing world About Policy Cures

4 3 reasons to focus on vaccine innovation When you don t When you do Impact

5 When you don t. Polio 1930

6 and polio 1950

7 When you do

8 2.5m lives saved annually from vaccination

9 Vaccine preventable diseases still offer the highest impact targets Global DALYs (2010) Malaria HIV/AIDS Diarrhoeal diseases Tuberculosis Bacterial pneumonia & meningitis Salmonella infections Helminth infections Rheumatic fever 83m 80m 66m 49m 38m 17m 12m 9m

10 Where are we today? The pipeline

11 The pipeline (2012) Number of candidates in Phase I/II Bacterial pneumonia and meningitis 4 Diarrhoeal diseases 12 HIV/AIDS 44 TB 13 Malaria 22 Helminth infections 1 Dengue 4 Salmonella infections 6 Number of candidates in Phase III Bacterial pneumonia and meningitis 1 Diarrhoeal diseases 4 HIV/AIDS 2 TB 1 Malaria 1 Helminth infections 1 Dengue 1

12 But we re now working on the toughest targets BUY old vaccines MMR, tetanus, diphtheria, polio, HiB ADAPT - recent vaccines for developing world use Pneumococcal, rotavirus, meningitis MAKE tough new targets HIV, TB, malaria, dengue

13 and it s a long road HIV vaccines all failed to date Frontrunner TB vaccine failed (MVA85A, 2013) Malaria vaccine - ~50% efficacy (RTS,S, 2013) Frontrunner dengue vaccine ~56% efficacy (Sanofi, 2012)

14 Where are we today? The funding

15 Millions Total Neglected Disease R&D funding $3,500 $3,000 $2,500 $2,000 $1,500 $1,000 $500 $ $3.5 billion invested in neglected disease R&D in 2012 ~40% on vaccine R&D *$3.1 bn in baseline 2007 USD

16 Millions Vaccine R&D funding $1,400 $1,200 $1,000 20% Philanthropic funding $800 $600 $400 $200 $ Public funding Industry funding Philanthropic funding 18% Industry funding 62% Public funding

17 Vaccine R&D funding (2012) Other 3% Diarrhoeal diseases 6% Bacterial Pneumonia & Meningitis 7% HIV/AIDS 50% TB 8% Malaria 11% Dengue 15%

18 Top funders of neglected disease vaccine R&D, NIH $484m 2 Pharmaceutical Industry $308m 3 Bill & Melinda Gates Foundation $193m 4 US D e p a r t m e n t of D e f e n s e ( D O D ) $ 60m 5 US Agency for International Development (USAID) $32m 6 European Commission: Research Directorate-General $22m 7 UK D e p a r t m e n t f o r I n t e r n a t i o n a l D e v e l o p m e n t ( D F I D ) $ 14m

19 HIV Vaccine R&D funding by funder type 2012 Philanthropic funding 11% Industry funding 3% Top funders HIV Vaccine R&D, US NIH $391m 2 Bill & Melinda Gates Foundation $63m 3 US DoD $41m 4 USAID $26m 5 Industry $16m 6 UK DFID $14m 7 European Commission $8m 8 Canadian CIDA $5m Public funding 85%

20 TB Vaccine R&D funding by funder type, 2012 Industry funding 27% Philanthropic funding 39% Top funders TB Vaccine R&D, Bill & Melinda Gates Foundation $36m 2 Industry $28m 3 US NIH $16m 4 European Commission $5m 5 Statens Serum Institute $4m 6 UK Medical Research Council $2m 7 The Wellcome Trust $2m 8 Dutch DGIS $2m Public funding 34%

21 Australia and global health vaccine R&D

22 Australia has been absent Funding is highly concentrated Top 8 funder <=$5m Even so, Australia doesn t appear

23 .but is it changing? First product development funding (2013) $2.5m to TB vaccines from AusAID The 2014 budget Me

24 Thank you